A detailed history of Beacon Pointe Advisors, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 23,000 shares of AVXL stock, worth $171,350. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,000
Previous 23,000 -0.0%
Holding current value
$171,350
Previous $97,000 34.02%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$3.39 - $5.02 $16,950 - $25,099
5,000 Added 27.78%
23,000 $97,000
Q4 2023

Feb 08, 2024

SELL
$5.04 - $9.95 $1,134 - $2,238
-225 Reduced 1.23%
18,000 $167,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $1,473 - $2,108
225 Added 1.25%
18,225 $119,000
Q1 2022

May 17, 2022

SELL
$9.74 - $17.69 $2,191 - $3,980
-225 Reduced 1.23%
18,000 $222,000
Q4 2020

Feb 12, 2021

BUY
$4.01 - $7.58 $73,082 - $138,145
18,225 New
18,225 $98,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Beacon Pointe Advisors, LLC Portfolio

Follow Beacon Pointe Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beacon Pointe Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beacon Pointe Advisors, LLC with notifications on news.